Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model
Briefings in Bioinformatics · 2024
DOI: 10.1093/bib/bbae108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2024. Verfasst von Adi Jabarin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU), P.O.B. 653, Beer-Sheva 8410501, Israel. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Repositioning, Deep Learning, Tetracyclines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Innovation Authority - Bio Convergence.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) remains a serious threat to health, with limited effective therapeutic options, especially due to advanced stage at diagnosis and its inherent resistance to chemotherapy, making it one of the leading causes of cancer-related deaths worldwide. The lack of clear treatment directions underscores the urgent need for innovative approaches to address and manage this deadly condition. In this research, we repurpose drugs with potential anti-cancer activity using machine learning (ML).
Methods
We tackle the problem by using a neural network trained on drug–target interaction information enriched with drug–drug interaction information, which has not been used for anti-cancer drug repurposing before. We focus on eravacycline, an antibacterial drug, which was selected and evaluated to assess its anti-cancer effects.
Results
Eravacycline significantly inhibited the proliferation and migration of BxPC-3 cells and induced apoptosis.
Conclusion
Our study highlights the potential of drug repurposing for cancer treatment using ML. Eravacycline showed promising results in inhibiting cancer cell proliferation, migration and inducing apoptosis in PDAC. These findings demonstrate that our developed ML drug repurposing models can be applied to a wide range of new oncology therapeutics, to identify potential anti-cancer agents. This highlights the potential and presents a promising approach for identifying new therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU), P.O.B. 653, Beer-Sheva 8410501, Israel.
- Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 8410501, Israel.
ORCID-Profile: Guy Shtar
Förderung
- Israel Innovation Authority - Bio Convergence
Zitieren
APA
Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Ben-Shabat, S., & Rokach, L. (2024). Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbae108
Vancouver
Jabarin A, Shtar G, Feinshtein V, Mazuz E, Shapira B, Ben-Shabat S, et al. Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model. Briefings in Bioinformatics. 2024. doi:10.1093/bib/bbae108
BibTeX
@article{Jabarin2024,
author = {Jabarin, Adi and Shtar, Guy and Feinshtein, Valeria and Mazuz, Eyal and Shapira, Bracha and Ben-Shabat, Shimon and Rokach, Lior},
title = {Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model},
journal = {Briefings in Bioinformatics},
year = {2024},
doi = {10.1093/bib/bbae108}
}
EUVIMED